Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. AZTR
AZTR logo

AZTR Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Azitra Inc (AZTR) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Sell
Latest Price
0.210
1 Day change
-1.83%
52 Week Range
2.660
Analysis Updated At
2026/04/17
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Azitra Inc (AZTR) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock exhibits weak financial performance, bearish technical indicators, and lacks positive catalysts or strong trading signals. Additionally, there is no evidence of insider or institutional interest, and no recent news or events to drive a potential upside.

Technical Analysis

The technical indicators for AZTR are bearish. The MACD histogram is negative and expanding downward, the RSI is neutral at 40.203, and moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below key support levels, with S1 at 0.211 and S2 at 0.201, suggesting further downside risk.

Positive Catalysts

  • NULL. There is no recent news, no significant insider or hedge fund activity, and no congress trading data to indicate positive sentiment or catalysts for the stock.

Neutral/Negative Catalysts

  • Weak financial performance in Q4 2025, with a YoY decline in net income (-6.67%), EPS (-90.38%), and gross margin (-100%). The stock also shows a lack of institutional and insider interest, and technical indicators suggest a bearish trend.

Financial Performance

In Q4 2025, the company reported zero revenue growth, a net income loss of -$2,233,504 (down -6.67% YoY), and a significant drop in EPS (-90.38% YoY). Gross margin fell to 0, down -100% YoY, indicating poor financial health.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst ratings or price target changes are available for AZTR.

Wall Street analysts forecast AZTR stock price to rise
Analyst Rating
0
Wall Street analysts forecast AZTR stock price to rise
Buy
Hold
Sell
0
Current: 0.215
sliders
Low
0
Averages
0
High
0
0
Current: 0.215
sliders
Low
0
Averages
0
High
0
Maxim
Buy
downgrade
$4
AI Analysis
2025-09-24
Reason
Maxim
Price Target
$4
AI Analysis
2025-09-24
downgrade
Buy
Reason
Maxim lowered the firm's price target on Azitra to $4 from split-adjusted $13.32 and keeps a Buy rating on the shares. The firm is citing its expectations of dilution in cutting its price target as the company addresses capital needs to advance ATR-12 and ATR-04 forward in clinical development, the analyst tells investors in a research note. Maxim adds however that Azitra's lead program ATR-12 in Netherton syndrome reported positive initial safety data in June, and if positive, its ongoing Phase 1 trial could be a key catalyst for shares.

People Also Watch